Qi Zhang

Qi Zhang

Auto-generated profile, based on publicly available information

Qi Zhang

Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TYTimothy A. Yap
Timothy A. Yap
Naval DaverNaval Daver
Naval Daver
MMMikhila Mahendra
Mikhila Mahendra
JZJixiang Zhang
Jixiang Zhang
CKCarlos Kamiya-Matsuoka
Carlos Kamiya-Matsuoka
MKMarina Konopleva
Marina Konopleva

21 February 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
QZQi Zhang
Qi Zhang
BRBridget Riley-Gillis
Bridget Riley-Gillis
LHLina Han
Lina Han
YJYannan Jia
Yannan Jia
ALAlessia Lodi
Alessia Lodi
MKMarina Konopleva
Marina Konopleva
Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. We performed gene/protein expression, metabolomic and methylation analyses of isogenic AML cell lines sensitive or resistant to VEN, and identified the activation of RAS/MAPK pathway, leading to increased stability and higher levels of MCL-1 protein, as a major acquired mechanism of VEN resistance. MCL-1 sustained survival and maintained mitochondrial respiration in VEN-RE cells, which had impaired electron transport chain (ETC) complex II activity, and MCL-1 silencing or pharmacologic inhibition restored VEN sensitivity. In support of the importance of RAS/MAPK activation, we found by single-cell DNA sequencing rapid clonal selection of RAS-mutated clones in AML patients treated with VEN-containing regimens. In summary, these findings establish RAS/MAPK/MCL-1 and mitochondrial fitness as key survival mechanisms of VEN-RE AML and provide the rationale for combinatorial strategies effectively targeting these pathways.

25 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDongwen Lv
Dongwen Lv
PPPratik Pal
Pratik Pal
XLXingui Liu
Xingui Liu
YJYannan Jia
Yannan Jia
DTDinesh Thummuri
Dinesh Thummuri
DZDaohong Zhou
Daohong Zhou
PROteolysis-TArgeting Chimeras (PROTACs) have emerged as an innovative drug development platform. However, most PROTACs have been generated empirically because many determinants of PROTAC specificity and activity remain elusive. Through computational modelling of the entire NEDD8-VHL Cullin RING E3 ubiquitin ligase (CRLVHL)/PROTAC/BCL-xL/UbcH5B(E2)-Ub/RBX1 complex, we find that this complex can only ubiquitinate the lysines in a defined band region on BCL-xL. Using this approach to guide our development of a series of ABT263-derived and VHL-recruiting PROTACs, we generate a potent BCL-xL and BCL-2 (BCL-xL/2) dual degrader with significantly improved antitumor activity against BCL-xL/2-dependent leukemia cells. Our results provide experimental evidence that the accessibility of lysines on a target protein plays an important role in determining the selectivity and potency of a PROTAC in inducing protein degradation, which may serve as a conceptual framework to guide the future development of PROTACs.

28 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCTianyu Cai
Tianyu Cai
AGAgnès Gouble
Agnès Gouble
KBKathryn L. Black
Kathryn L. Black
ASAnna Skwarska
Anna Skwarska
ANAmmar S. Naqvi
Ammar S. Naqvi
MKMarina Konopleva
Marina Konopleva
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially expressed on the surface of BPDCN cells, it has emerged as an attractive therapeutic target. UCART123 is an investigational product consisting of allogeneic T cells expressing an anti-CD123 chimeric antigen receptor (CAR), edited with TALEN® nucleases. In this study, we examine the antitumor activity of UCART123 in preclinical models of BPDCN. We report that UCART123 have selective antitumor activity against CD123-positive primary BPDCN samples (while sparing normal hematopoietic progenitor cells) in the in vitro cytotoxicity and T cell degranulation assays; supported by the increased secretion of IFNγ by UCART123 cells when cultured in the presence of BPDCN cells. UCART123 eradicate BPDCN and result in long-term disease-free survival in a subset of primary patient-derived BPDCN xenograft mouse models. One potential challenge of CD123 targeting therapies is the loss of CD123 antigen through diverse genetic mechanisms, an event observed in one of three BPDCN PDX studied. In summary, these results provide a preclinical proof-of-principle that allogeneic UCART123 cells have potent anti-BPDCN activity.

21 April 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
YJYannan Jia
Yannan Jia
WZWeiguo Zhang
Weiguo Zhang
MBMahesh Basyal
Mahesh Basyal
KCKyung Hee Chang
Kyung Hee Chang
LOLauren Ostermann
Lauren Ostermann
MAMichael Andreeff
Michael Andreeff

14 February 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
SBSeemana Bhattacharya
Seemana Bhattacharya
SPSujan Piya
Sujan Piya
HMHuaxian Ma
Huaxian Ma
PSPriyanka Sharma
Priyanka Sharma
QZQi Zhang
Qi Zhang
GBGautam Borthakur
Gautam Borthakur
Despite effective new therapies, adaptive resistance remains the main obstacle in acute myelogenous leukemia (AML) therapy. Autophagy induction is a key mechanism for adaptive resistance. Leukemic blasts at diagnosis express higher levels of the apical autophagy kinase ULK1 compared with normal hematopoietic cells. Exposure to chemotherapy and targeted agents upregulate ULK1, hence we hypothesize that developing ULK1 inhibitors may present the unique opportunity for clinical translation of autophagy inhibition. Accordingly, we demonstrate that ULK1 inhibition, by genetic and pharmacologic means, suppresses treatment-induced autophagy, overcomes adaptive drug-resistance, and synergizes with chemotherapy and emerging antileukemia agents like venetoclax (ABT-199). The study next aims at exploring the underlying mechanisms. Mechanistically, ULK1 inhibition downregulates MCL1 antiapoptotic gene, impairs mitochondrial function and downregulates components of the CD44-xCT system, resulting in impaired reactive oxygen species (ROS) mitigation, DNA damage, and apoptosis. For further validation, several mouse models of AML were generated. In these mouse models, ULK1 deficiency impaired leukemic cell homing and engraftment, delayed disease progression, and improved survival. Therefore, in the study, we validated our hypothesis and identified ULK1 as an important mediator of adaptive resistance to therapy and an ideal candidate for combination therapy in AML. Therefore, we propose ULK1 inhibition as a therapeutically relevant treatment option to overcome adaptive drug-resistance in AML. Implications: ULK1 drives a cell-intrinsic adaptive resistance in AML and targeting ULK1-mediated autophagy can synergize with existing and emerging AML therapies to overcome drug-resistance and induce apoptosis.